Core Insights - The Beauty Health Company (SKIN) reported a revenue of $70.7 million for the quarter ended September 2025, reflecting a 10.3% decline year-over-year [1] - The company's EPS was -$0.09, an improvement from -$0.15 in the same quarter last year, but below the consensus estimate of -$0.08, resulting in a surprise of -12.5% [1] - The revenue exceeded the Zacks Consensus Estimate of $68.75 million by 2.84% [1] Revenue Breakdown - Geographic Revenue in the Americas was $48.3 million, surpassing the estimated $46.45 million, but down 6.9% from the previous year [4] - EMEA revenue stood at $16.1 million, slightly above the estimated $15.94 million, with no year-over-year change [4] - Asia Pacific revenue was $6.3 million, exceeding the estimate of $6 million, but down significantly by 41.7% compared to the year-ago quarter [4] Sales Performance - Delivery Systems Net Sales reached $20.8 million, exceeding the estimate of $17.03 million, but down 24.6% year-over-year [4] - Consumables Net Sales were reported at $49.8 million, slightly below the estimated $51.36 million, reflecting a 2.7% decline from the previous year [4] Stock Performance - Over the past month, shares of Beauty Health have declined by 13.5%, contrasting with a 1.3% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Hudson Pacific Properties (HPP) reported a revenue of $186.62 million for the quarter ended September 2025, which is a decrease of 6.9% compared to the same period last year [1] - The earnings per share (EPS) for the quarter was $0.04, a significant improvement from -$0.69 in the year-ago quarter, indicating a 100% surprise against the consensus estimate of $0.02 [1] Revenue Breakdown - Office Rental revenues were $148.29 million, falling short of the average estimate of $151.05 million, representing a year-over-year decline of 9% [4] - Office Service and other revenues reached $6.29 million, exceeding the average estimate of $4.65 million, marking a year-over-year increase of 55.9% [4] - Total Studio revenues were $32.04 million, below the average estimate of $34.32 million, reflecting a decrease of 4.2% year over year [4] - Studio Service and other revenues were $18.47 million, compared to the estimated $21.85 million, showing a decline of 6.4% from the previous year [4] - Total Office revenues amounted to $154.58 million, slightly below the average estimate of $155.7 million, with a year-over-year decrease of 7.4% [4] - Studio Rental revenues were reported at $13.57 million, surpassing the average estimate of $12.48 million, with a year-over-year change of -1.1% [4] Stock Performance - Over the past month, Hudson Pacific shares have returned -16.7%, contrasting with the Zacks S&P 500 composite's increase of +1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $458.58 million for the quarter ended September 2025, marking a year-over-year increase of 133% [1] - The earnings per share (EPS) for the same period was $1.67, a significant improvement from -$0.46 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $366.21 million by 25.22%, while the EPS surprise was 62.14% above the consensus estimate of $1.03 [1] Revenue Breakdown - Product revenue, net was $177.76 million, slightly below the nine-analyst average estimate of $178.43 million, reflecting a year-over-year change of 0.7% [4] - Licensing and other revenue reached $280.82 million, significantly surpassing the estimated $126.67 million, representing a year-over-year increase of 1286.2% [4] - Product Revenue from EMPAVELI was $26.83 million, exceeding the average estimate of $22.06 million, with a year-over-year change of 9% [4] - Product Revenue from SYFOVRE was $150.93 million, slightly below the average estimate of $156.55 million, showing a year-over-year decrease of 0.7% [4] Stock Performance - Shares of Apellis Pharmaceuticals have returned +30.1% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - HF Sinclair reported $7.25 billion in revenue for Q3 2025, a year-over-year increase of 0.6%, with an EPS of $2.44 compared to $0.51 a year ago, exceeding Zacks Consensus Estimates for revenue and EPS [1] - The company demonstrated strong performance metrics, with a stock return of +3.8% over the past month, outperforming the S&P 500 composite's +3.6% change, and holds a Zacks Rank 1 (Strong Buy) [3] Financial Performance - Revenue of $7.25 billion surpassed the Zacks Consensus Estimate of $7.02 billion, resulting in a surprise of +3.33% [1] - EPS of $2.44 exceeded the consensus estimate of $1.94, leading to an EPS surprise of +25.77% [1] - Consolidated average per produced barrel adjusted refinery gross margin was $19.16, above the $16.42 average estimate [4] - Sales of produced refined products totaled 661.14 million barrels, slightly below the estimated 667.52 million barrels [4] Regional Performance - In the West Region, the average per produced barrel adjusted refinery gross margin was $20.38, exceeding the estimated $18.05 [4] - Mid-Continent Region sales of produced refined products reached 281.04 million barrels, surpassing the estimate of 275.08 million barrels [4] - Average per produced barrel adjusted refinery gross margin in the Mid-Continent Region was $17.5, compared to the $14.12 estimate [4] Revenue Breakdown - Sales and other revenues from lubricants and specialties were $655 million, below the estimate of $704.88 million, reflecting a year-over-year decline of -4.5% [4] - Midstream revenues were $160 million, slightly below the estimated $165.38 million, representing a -2.4% change year-over-year [4] - Marketing revenues were $898 million, slightly above the estimate of $893.54 million, with a year-over-year change of -5.5% [4] - Refining revenues were reported at $6.44 billion, exceeding the estimate of $4.4 billion, with a +1% change year-over-year [4] - Renewables revenues reached $277 million, significantly above the estimate of $170.97 million, marking a +4.4% change year-over-year [4] - Corporate, Other and Eliminations reported revenues of -$1.18 billion, slightly below the estimate of -$1.15 billion, reflecting a -4.7% change year-over-year [4]

Core Insights - Equinix reported revenue of $2.32 billion for the quarter ended September 2025, reflecting a year-over-year increase of 5.2% and an EPS of $9.83, significantly higher than the $3.10 from the same quarter last year [1] - The revenue was slightly below the Zacks Consensus Estimate by 0.32%, while the EPS exceeded the consensus estimate by 6.16% [1] Financial Performance Metrics - Equinix's shares returned +4.2% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change, with a current Zacks Rank of 3 (Hold) [3] - In the Asia-Pacific region, Cabinet Equivalent Capacity was reported at 91,000, slightly above the estimated 90,875 [4] - Worldwide Cabinet Billing was 295,000, marginally below the average estimate of 296,392 [4] - Geographic Revenues for Asia-Pacific were $497 million, underperforming the estimate of $511.76 million, representing a year-over-year decline of 0.6% [4] - Americas Geographic Revenues reached $1.04 billion, exceeding the estimate of $1.02 billion, with an 8% year-over-year increase [4] - EMEA Geographic Revenues were $784 million, slightly below the estimate of $788.31 million, showing a 5.5% year-over-year increase [4] - Recurring revenues totaled $2.32 billion, surpassing the estimated $2.2 billion, marking a 12.5% increase year-over-year [4] - Non-recurring revenues were reported at $101 million, significantly lower than the estimated $126.04 million, reflecting a 28.9% year-over-year decline [4] - Managed infrastructure recurring revenues were $118 million, slightly below the estimate of $119.73 million, showing no change year-over-year [4] - Interconnection recurring revenues were $422 million, exceeding the estimate of $417.01 million, with a year-over-year increase of 9.9% [4]

Core Insights - Legget & Platt reported revenue of $1.04 billion for the quarter ended September 2025, a decrease of 5.9% year-over-year, with EPS at $0.29 compared to $0.32 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $1.02 billion by 1.18%, while the EPS fell short of the consensus estimate of $0.30 by 3.33% [1] Financial Performance - Organic Sales for Bedding Products decreased by 9%, slightly worse than the average estimate of -8.7% [4] - Organic Sales for Specialized Products decreased by 2%, in line with the average estimate of -2.5% [4] - Overall Organic Sales declined by 4%, better than the average estimate of -5.7% [4] Trade Sales - Trade sales for Furniture, Flooring, and Textile Products were reported at $356.4 million, exceeding the average estimate of $347.31 million, with no year-over-year change [4] - Trade sales for Specialized Products were $277.5 million, surpassing the average estimate of $273.04 million, representing a 7.5% decline year-over-year [4] - Trade sales for Bedding Products were $402.5 million, slightly below the average estimate of $406.4 million, reflecting a 9.7% decrease year-over-year [4] EBIT Performance - EBIT for Bedding Products was reported at $36.4 million, significantly higher than the average estimate of $19.21 million [4] - EBIT for Specialized Products reached $112.9 million, compared to the average estimate of $33.04 million [4] - Adjusted EBIT for Specialized Products was $27 million, slightly above the average estimate of $26.6 million, while Adjusted EBIT for Bedding Products was $26.4 million, exceeding the average estimate of $23.25 million [4]

Core Insights - Plexus (PLXS) reported revenue of $1.06 billion for the quarter ended September 2025, marking a year-over-year increase of 0.7% and an EPS of $2.14, up from $1.85 a year ago, indicating strong earnings performance [1] - The revenue exceeded the Zacks Consensus Estimate of $1.05 billion by 1.16%, while the EPS surpassed the consensus estimate of $1.84 by 16.3% [1] Financial Performance Metrics - Plexus shares have returned +3.4% over the past month, outperforming the Zacks S&P 500 composite's +1.1% change, with a current Zacks Rank of 3 (Hold), suggesting potential performance in line with the broader market [3] - Revenue breakdown by market sector includes: - Healthcare/Life Sciences: $424 million, below the average estimate of $433.16 million, with a year-over-year change of +2.2% [4] - Aerospace/Defense: $173 million, below the average estimate of $183.12 million, with a year-over-year change of -6% [4] - Industrial: $461 million, exceeding the average estimate of $430.41 million, with a year-over-year change of +2% [4]

Core Insights - Sabre reported revenue of $687.15 million for the quarter ended June 2025, reflecting a 10.4% decline year-over-year and a surprise of -2.58% compared to the Zacks Consensus Estimate of $705.31 million [1] - The company's EPS was -$0.02, an improvement from -$0.05 in the same quarter last year, with no EPS surprise against the consensus estimate of $0 [1] Financial Performance Metrics - Travel Solutions - Air Bookings were 75.53 million, below the average estimate of 79.36 million [4] - Total Bookings in Travel Solutions reached 90.3 million, compared to the estimated 94.61 million [4] - Passengers Boarded in Travel Solutions totaled 171.35 million, slightly below the estimate of 173.95 million [4] - Lodging, Ground and Sea Bookings were 14.76 million, compared to the average estimate of 15.25 million [4] - Distribution Revenue in Travel Solutions was $545.77 million, below the estimate of $567.37 million, marking a year-over-year change of -0.9% [4] - Overall Revenue for Travel Solutions was $687.15 million, compared to the estimated $708.09 million, reflecting a year-over-year change of -1.1% [4] - IT Solutions Revenue within Travel Solutions was $141.38 million, slightly above the estimate of $140.72 million, with a year-over-year change of -2.1% [4] Stock Performance - Sabre's shares have returned -6.3% over the past month, contrasting with the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Fastly reported revenue of $148.71 million for the quarter ended June 2025, reflecting a year-over-year increase of 12.3% [1] - The company's EPS was -$0.03, an improvement from -$0.07 in the same quarter last year, with a surprise of +40% compared to the consensus estimate of -$0.05 [1] - Fastly's revenue exceeded the Zacks Consensus Estimate of $145.07 million by 2.51% [1] Financial Performance Metrics - Fastly's enterprise customer count reached 622, surpassing the two-analyst average estimate of 600 [4] - Revenue from enterprise customers was $139.26 million, exceeding the average estimate of $135.45 million, marking a year-over-year increase of 15.4% [4] - Revenue by product included $4.5 million from Other, slightly above the average estimate of $4.47 million, $29.3 million from Security, compared to the average estimate of $29.65 million, and $114.9 million from Network Services, exceeding the average estimate of $111.21 million [4] Stock Performance - Fastly's shares have declined by 12.7% over the past month, while the Zacks S&P 500 composite increased by 0.5% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Nutrien reported revenue of $10.44 billion for the quarter ended June 2025, a year-over-year increase of 2.8% and an EPS of $2.65 compared to $2.34 a year ago, indicating positive growth in earnings [1] - The revenue fell short of the Zacks Consensus Estimate of $10.61 billion, resulting in a surprise of -1.62%, while the EPS exceeded expectations by +10.42% against a consensus estimate of $2.40 [1] Financial Performance Metrics - Potash sales volumes reached 3,989 KTon, surpassing the average estimate of 3,613.10 KTon [4] - Nitrogen sales volumes totaled 3,017 KTon, exceeding the average estimate of 2,947.19 KTon [4] - The average selling price per tonne for phosphate (industrial and feed) was $821.00, higher than the estimated $754.85 [4] - Retail sales (Nutrient Ag Solutions) amounted to $7.96 billion, below the estimated $8.4 billion, reflecting a -1.4% change year-over-year [4] - Nitrogen sales were reported at $1.41 billion, exceeding the average estimate of $1.25 billion, representing a +19% year-over-year change [4] - Phosphate sales were $449 million, slightly above the average estimate of $436.29 million, with a year-over-year change of -0.4% [4] - Potash sales reached $1.09 billion, surpassing the average estimate of $892.38 million, indicating a +29.8% year-over-year change [4] - Net sales for potash were $991 million, exceeding the average estimate of $794.77 million, reflecting a +31.1% year-over-year change [4] - Net sales for nitrogen were $1.26 billion, above the average estimate of $1.08 billion, representing a +22.6% change year-over-year [4] - Net sales for phosphate were $396 million, slightly below the average estimate of $418.63 million, with a +0.5% year-over-year change [4] Stock Performance - Nutrien's shares have returned -3.7% over the past month, contrasting with the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]